FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Miller, Kathleen L.
Miller Needleman, Katherine I.
Text and Data Mining valid from 2020-09-03
Version of Record valid from 2020-09-03
29 April 2020
19 August 2020
3 September 2020
Ethics approval and consent to participate
The authors declare that they have no competing interests.